Publication of memorandum
Initiator Pharma A/S ("Initiator Pharma") hereby publishes memorandum for the company's rights issue of units, the subscription period commencing on June 2, 2020. The memorandum is available on Initiator Pharma’s (www.initiatorpharma.com) and Spotlight Stock Market’s (www. spotlightstockmarket.com) respective websites. In addition, the memorandum can be accessed via the Sedermera Fondkommission’s website (www.sedermera.se). The teaser and registration form will be published on the above-mentioned websites in connection with the start of the subscription period.
Financial advisor, issuer and legal advisor
Sedermera Fondkommission is the financial advisor and issuing agent of Initiator Pharma in connection with the rights issue.
For more information about the rights issue, please contact:
Telephone number: +46 40 615 14 10
For more information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone number: +45 6126 0035
About Initiator Pharma
Initiator Pharma is a biotechnology company based in Aarhus, Denmark. The company’s main asset, IPED2015, is a candidate drug intended for patients with erectile dysfunction. The treatment is expected to improve the quality of life for a growing number of patients who are not responding to or cannot be treated with existing drugs on the market. Read more on www.initiatorpharma.com.
About erectile disfunction
ED is sexual dysfunction characterized by the inability to achieve or maintain an erection during intercourse. More than 150 million men worldwide suffer from ED, a number that is expected to increase to over 320 million by 2025 due to an aging population and increased prevalence of lifestyle diseases such as diabetes. ED leads to impaired quality of life in patients through various psychosocial factors such as low self-esteem, depression, depression, anger, frustration, anxiety, relationship problems (1, 2, 3).